GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (NAS:EVOK) » Definitions » Equity-to-Asset

Evoke Pharma (Evoke Pharma) Equity-to-Asset

: -0.37 (As of Dec. 2023)
View and export this data going back to 2013. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Evoke Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-2.58 Mil. Evoke Pharma's Total Assets for the quarter that ended in Dec. 2023 was $7.07 Mil. Therefore, Evoke Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.37.

The historical rank and industry rank for Evoke Pharma's Equity-to-Asset or its related term are showing as below:

EVOK' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.37   Med: 0.35   Max: 0.71
Current: -0.37

During the past 13 years, the highest Equity to Asset Ratio of Evoke Pharma was 0.71. The lowest was -0.37. And the median was 0.35.

EVOK's Equity-to-Asset is ranked worse than
92.09% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs EVOK: -0.37

Evoke Pharma Equity-to-Asset Historical Data

The historical data trend for Evoke Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 -0.34 0.34 0.35 -0.37

Evoke Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.21 0.06 -0.11 -0.37

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evoke Pharma Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Evoke Pharma's Equity-to-Asset falls into.



Evoke Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Evoke Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-2.58/7.069
=-0.36

Evoke Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-2.58/7.069
=-0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evoke Pharma  (NAS:EVOK) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Evoke Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Evoke Pharma (Evoke Pharma) Business Description

Traded in Other Exchanges
Address
420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Executives
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David A Gonyer director, officer: President and CEO C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Matthew J D'onofrio officer: Exec VP, Chief Bus. Officer C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Lvp Gp Iii, Llc 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Kenneth J Widder director, 10 percent owner 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Dp Vii Associates Lp 10 percent owner ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Domain Parters Vii L P 10 percent owner ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Nimesh Shah 10 percent owner 12481 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO CA 92130
Marilyn R. Carlson officer: Chief Medical Officer C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Todd C Brady director C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Scott L Glenn director
Lvpmc, Llc 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Partners Lp 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Associates, L.p. 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111

Evoke Pharma (Evoke Pharma) Headlines

From GuruFocus